Caribou Biosciences Inc Dossier
Qualitative Analysis
Business overview
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a leading clinical-stage CRISPR genome-editing biopharmaceutical company co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, Ph.D., and CEO Rachel Haurwitz, Ph.D.. The company is dedicated to developing transformative, off-the-shelf (allogeneic) CAR-T cell therapies for patients with devastating hematologic malignancies. At the core of Caribou's pipeline is its proprietary CRISPR hybrid RNA-DNA (chRDNA) genome-editing technology, which provides superior precision, specificity, and efficiency compared to first-generation CRISPR systems, enabling multiplex editing while maintaining genomic integrity.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In April 2025, Caribou implemented a major strategic restructuring to focus resources exclusively on its lead clinical-stage oncology programs, vispa-cel (CB-010) and CB-011. As part of this initiative, the company discontinued its GALLOP Phase 1 trial of vispa-cel in lupus, the AMpLify Phase 1 trial of CB-012 in acute myeloid leukemia, and all preclinical research. Additionally, Caribou reduced its workforce by approximately 32% (47 employees).
Expected impact: Extended the company's cash runway by approximately one full year, pushing funding sufficiency from H2 2026 into H2 2027 to preserve capital for lead clinical assets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Pfizer made a strategic equity investment to support the clinical development of Caribou's allogeneic CAR-T programs, specifically CB-011. Under the terms, Pfizer has certain information-sharing rights and a right of first negotiation on the program.
Terms: $25.0 million equity investment.
Provides Caribou with non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for the development of its CRISPR-edited allogeneic cell therapies.
Terms: Platform licensing terms including undisclosed development, regulatory, and commercial milestones, plus sales royalties.